Published Date: 17 May 2024
In contrast to previous estimates of less than 5%, the study computes a rate of 7 points 1 percent.
Read Full NewsA new study led by University of Manchester scientists has identified genetic variants that make some patients more sensitive to radiation in specific parts of the rectum than others. The knowledge could reduce the risk of ...
Cancer is a challenging enough diagnosis, but many patients are dealt a second blow, even as they heal: "chemo brain."
1.
AI is useful in low-resource areas for triaging breast masses.
2.
In a randomized trial, the kinder, gentler regimen for classical Hodgkin wins out.
3.
In cases of locally advanced, potentially curable pancreatic cancer, a combination of drugs enhances the results of radiation therapy.
4.
Early Results for Anorexia Nervosa with Psilocybin.
5.
Approved BTK Inhibitor Without Covalent Bond for CLL.
1.
Cancer Staging: Updates, Clinical Insights, and Educational Resources for Medical Professionals
2.
TAR-200 in Bladder Cancer: Precision Drug Delivery Driving Oncology Advances
3.
PARP Inhibitors in Testicular Cancer: Tackling Cisplatin Resistance with Precision
4.
The Architect's Dilemma: Remodeling the Tumor Microenvironment for a New Era of Cancer Immunotherapy
5.
Unlocking the Potential of Immune Checkpoint Inhibitors: A Pioneering Case Series on the Role of Immunotherapy in Microsatellite-Instability-High Colorectal Cancer
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
2.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
4.
Virtual Case Study on Pedal Edema and Triple Vessel Disease - An Initiative by Hidoc Dr.
5.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation